Type I diabetes mellitus (T1DM), also known as insulin-dependent diabetes, is an autoimmune disease where the immune system attacks and destroys pancreatic ß cells. Hence little or no insulin is produced to facilitate the uptake of glucose. Clinically, T1DM is marked by fluctuations in glycemic readings and poor glycemic control.

Oramed’s oral insulin capsule (ORMD-0801) is anticipated for use as a complementary agent to insulin injections in the treatment of T1DM. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM.